Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M1-c6v1 Combined with Camrelizumab and Apatinib in Advanced HCC
NCT04665362Phase 1Unknown
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Oncolytic Viruses
01
Overview
Phase 1, open-label, single-arm trial of VRT-106 in hepatocellular carcinoma (HCC). Primary endpoint: Treatment related adverse events at 90 days. Status: unknown.
02
Drugs
VRT-106
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04665362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665362.